Bruce L Gilliam
Overview
Explore the profile of Bruce L Gilliam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zafar S, Gilliam B, Schmalzle S
Antivir Ther
. 2023 Dec;
28(6):13596535231218875.
PMID: 38048138
No abstract available.
2.
Priest J, Hulbert E, Gilliam B, Burton T
Open Forum Infect Dis
. 2021 Dec;
8(12):ofab562.
PMID: 34934773
Background: This retrospective administrative claims study aimed to describe clinical characteristics, health care resource utilization (HCRU), and costs of people with HIV (PWH) in US commercial and Medicare Advantage health...
3.
Chua J, Davis C, Husson J, Nelson A, Prado I, Flinko R, et al.
Vaccine
. 2021 Jun;
39(29):3879-3891.
PMID: 34099328
A major challenge for HIV vaccine development is to raise anti-envelope antibodies capable of recognizing and neutralizing diverse strains of HIV-1. Accordingly, a full length single chain (FLSC) of gp120-CD4...
4.
Bork J, Heil E, Berry S, Lopes E, Dave R, Gilliam B, et al.
Infect Dis Ther
. 2019 May;
8(2):171-184.
PMID: 31054088
Introduction: Dalbavancin is approved for acute bacterial skin and skin structure infections (ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive infections. Importantly, dalbavancin's real benefits may be...
5.
Claassen C, Keckich D, Nwizu C, Abimiku A, Salami D, Obiefune M, et al.
J Int Assoc Provid AIDS Care
. 2019 Feb;
18:2325958218823209.
PMID: 30798695
Background: Characterizing viral response to lopinavir/ritonavir (LPV/r) monotherapy as second-line treatment may guide recommendations for resource-limited settings (RLS). Methods: We conducted a 48-week prospective, single-arm study of LPV/r monotherapy in...
6.
Heil E, Bork J, Schmalzle S, Kleinberg M, Kewalramani A, Gilliam B, et al.
Open Forum Infect Dis
. 2016 Oct;
3(3):ofw155.
PMID: 27704011
A large percentage of patients presenting to acute care facilities report penicillin allergies that are associated with suboptimal antibiotic therapy. Penicillin skin testing (PST) can clarify allergy histories but is...
7.
Schmalzle S, Buchwald U, Gilliam B, Riedel D
Mycoses
. 2016 Mar;
59(9):542-52.
PMID: 26932366
Cryptococcosis is an opportunistic invasive fungal infection that is well described and easily recognised when it occurs as meningitis in HIV-infected persons. Malignancy and its treatment may also confer a...
8.
OConnell R, Excler J, Polonis V, Ratto-Kim S, Cox J, Jagodzinski L, et al.
J Infect Dis
. 2016 Feb;
213(12):1946-54.
PMID: 26908741
Background: Prime-boost regimens comprising ALVAC-HIV (prime) and human immunodeficiency virus type 1 (HIV) Env (boost) induce HIV-specific neutralizing antibody and cell-mediated immune responses, but the impact of boost schedule and...
9.
Taremi M, Kleinberg M, Wang E, Gilliam B, Ryscavage P
Ann Clin Microbiol Antimicrob
. 2015 Nov;
14:50.
PMID: 26576545
Background: The diagnosis of invasive pulmonary aspergillosis is challenging. It is unclear whether galactomannan (GM) results from bronchial wash (BW) and bronchoalveolar lavage (BAL) samples differ in a clinically meaningful...
10.
Sowah L, Buchwald U, Riedel D, Gilliam B, Khambaty M, Fantry L, et al.
J Int Assoc Provid AIDS Care
. 2015 Aug;
14(6):497-504.
PMID: 26307210
In this article, we sought to understand the perceptions and practice of providers on anal cancer screening in HIV-infected patients. Providers in an academic outpatient HIV practice were surveyed. Data...